CE-mark for RayMedica's PDN (prosthetic disc nucleus):
This article was originally published in Clinica
Executive Summary
RayMedica has CE-marked its prosthetic disc nucleus, designed for treating degenerative disc disease which results in chronic and debilitating back pain. The tiny pillow-shaped device is intended as an alternative to a discectomy, the removal of the spinal disc, and is implanted inside the degenerating disc. It restores the disc's ability to separate the bones of the spine and act as a shock absorber, relieving pressure on nearby nerves. The company has carried out clinical studies on its device in five countries including the US.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.